OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations
Jeremy D. Rubinstein, Maureen M. O’Brien
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Jeremy D. Rubinstein, Maureen M. O’Brien
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 7
Showing 7 citing articles:
The bisintercalator family of nonribosomal peptides: structural diversity and biosynthetic mechanism
Xinjie Shi
Natural Product Reports (2025)
Closed Access
Xinjie Shi
Natural Product Reports (2025)
Closed Access
Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions
Hagop M. Kantarjian, Nicolas Boissel, Cristina Papayannidis, et al.
Cancer (2024)
Closed Access | Times Cited: 2
Hagop M. Kantarjian, Nicolas Boissel, Cristina Papayannidis, et al.
Cancer (2024)
Closed Access | Times Cited: 2
Negative Impact of Gemtuzumab Ozogamicin on CD33-Positive Early T-Cell Precursor Acute Lymphoblastic Leukemia: A Case Report
Osamu Imataki, Haruyuki Fujita, Makiko Uemura
Case Reports in Oncology (2024) Vol. 17, Iss. 1, pp. 264-269
Open Access | Times Cited: 1
Osamu Imataki, Haruyuki Fujita, Makiko Uemura
Case Reports in Oncology (2024) Vol. 17, Iss. 1, pp. 264-269
Open Access | Times Cited: 1
Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia
Amber Gibson, César Núñez, Lindsay Robusto, et al.
Haematologica (2024)
Open Access | Times Cited: 1
Amber Gibson, César Núñez, Lindsay Robusto, et al.
Haematologica (2024)
Open Access | Times Cited: 1
Dermatologic Toxicities of Antibody-Drug Conjugates
Christian Gronbeck, Matthew J. Hadfield, Jane M. Grant‐Kels
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1177-1188
Closed Access | Times Cited: 1
Christian Gronbeck, Matthew J. Hadfield, Jane M. Grant‐Kels
Journal of the American Academy of Dermatology (2024) Vol. 91, Iss. 6, pp. 1177-1188
Closed Access | Times Cited: 1
’Roids without rage via B-cell–targeted ADC?
Rachel E. Rau
Blood (2024) Vol. 144, Iss. 7, pp. 686-687
Closed Access
Rachel E. Rau
Blood (2024) Vol. 144, Iss. 7, pp. 686-687
Closed Access
Case of B-acute lymphoblastic leukaemia with t(1;19)(q23;p13.3)TCF3::PBX1and co-occurringCBLmutation in an elderly patient
Kenneth M. Zabel, Ryan W. Rebbe, Mohammad A. Vasef, et al.
BMJ Case Reports (2024) Vol. 17, Iss. 9, pp. e260617-e260617
Closed Access
Kenneth M. Zabel, Ryan W. Rebbe, Mohammad A. Vasef, et al.
BMJ Case Reports (2024) Vol. 17, Iss. 9, pp. e260617-e260617
Closed Access
